MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway
Zhen Liang(Capital Medical University), Ben Liu(Yichun University), Liping Xie(First Affiliated Hospital Zhejiang University), Jian Wu(Sun Yat-sen University), Shuai Meng(Capital Medical University), Yi Zhu(Xuzhou Medical College), Zhenghui Hu(First Affiliated Hospital Zhejiang University), Xin Xu(Shanghai University of Sport), Alin Ji(Zhejiang Provincial People's Hospital), Xiao Wang(Qingdao University), Shiqi Li(Zhejiang University), Xiangyi Zheng(Tianjin University), Bo Xie(Sun Yat-sen University), Yiwei Lin(First Affiliated Hospital Zhejiang University)
Cited by 92
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
|Molecular Cancer|2020|383
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276